These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 30503838)

  • 1. A nanodelivered Vorinostat derivative is a promising oral compound for the treatment of visceral leishmaniasis.
    Corpas-López V; Díaz-Gavilán M; Franco-Montalbán F; Merino-Espinosa G; López-Viota M; López-Viota J; Belmonte-Reche E; Pérez-Del Palacio J; de Pedro N; Gómez-Vidal JA; Morillas-Márquez F; Martín-Sánchez J
    Pharmacol Res; 2019 Jan; 139():375-383. PubMed ID: 30503838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (-)-α-Bisabolol, a Promising Oral Compound for the Treatment of Visceral Leishmaniasis.
    Corpas-López V; Morillas-Márquez F; Navarro-Moll MC; Merino-Espinosa G; Díaz-Sáez V; Martín-Sánchez J
    J Nat Prod; 2015 Jun; 78(6):1202-7. PubMed ID: 26076227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of water extract of green propolis and liposomal meglumine antimoniate in the treatment of experimental visceral leishmaniasis.
    Ferreira FM; Castro RA; Batista MA; Rossi FM; Silveira-Lemos D; Frézard F; Moura SA; Rezende SA
    Parasitol Res; 2014 Feb; 113(2):533-43. PubMed ID: 24292604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The in vivo activity of 1,3,4-thiadiazolium-2-aminide compounds in the treatment of cutaneous and visceral leishmaniasis.
    Rodrigues RF; Charret KS; Campos MC; Amaral V; Echevarria A; Dos Reis C; Canto-Cavalheiro MM; Leon LL
    J Antimicrob Chemother; 2012 Jan; 67(1):182-90. PubMed ID: 21987238
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Corpas-López V; Tabraue-Chávez M; Sixto-López Y; Panadero-Fajardo S; Alves de Lima Franco F; Domínguez-Seglar JF; Morillas-Márquez F; Franco-Montalbán F; Díaz-Gavilán M; Correa-Basurto J; López-Viota J; López-Viota M; Pérez Del Palacio J; de la Cruz M; de Pedro N; Martín-Sánchez J; Gómez-Vidal JA
    J Med Chem; 2020 Jun; 63(11):5734-5751. PubMed ID: 32392053
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of lapachol on treatment of cutaneous and visceral leishmaniasis.
    Araújo IAC; de Paula RC; Alves CL; Faria KF; Oliveira MM; Mendes GG; Dias EMFA; Ribeiro RR; Oliveira AB; Silva SMD
    Exp Parasitol; 2019 Apr; 199():67-73. PubMed ID: 30797783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An effective in vitro and in vivo antileishmanial activity and mechanism of action of 8-hydroxyquinoline against Leishmania species causing visceral and tegumentary leishmaniasis.
    Costa Duarte M; dos Reis Lage LM; Lage DP; Mesquita JT; Salles BC; Lavorato SN; Menezes-Souza D; Roatt BM; Alves RJ; Tavares CA; Tempone AG; Coelho EA
    Vet Parasitol; 2016 Feb; 217():81-8. PubMed ID: 26827866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis.
    Soyer TG; Mendonça DVC; Tavares GSV; Lage DP; Dias DS; Ribeiro PAF; Perin L; Ludolf F; Coelho VTS; Ferreira ACG; Neves PHAS; Matos GF; Chávez-Fumagalli MA; Coimbra ES; Pereira GR; Coelho EAF; Antinarelli LMR
    Exp Parasitol; 2019 Apr; 199():30-37. PubMed ID: 30817917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mixed formulation of conventional and pegylated liposomes as a novel drug delivery strategy for improved treatment of visceral leishmaniasis.
    Azevedo EG; Ribeiro RR; da Silva SM; Ferreira CS; de Souza LE; Ferreira AA; de Oliveira E Castro RA; Demicheli C; Rezende SA; Frézard F
    Expert Opin Drug Deliv; 2014 Oct; 11(10):1551-60. PubMed ID: 24962630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing the therapeutic efficacy of different amphotericin B-carrying delivery systems against visceral leishmaniasis.
    Mendonça DVC; Martins VT; Lage DP; Dias DS; Ribeiro PAF; Carvalho AMRS; Dias ALT; Miyazaki CK; Menezes-Souza D; Roatt BM; Tavares CAP; Barichello JM; Duarte MC; Coelho EAF
    Exp Parasitol; 2018 Mar; 186():24-35. PubMed ID: 29448040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of aminosidine administered alone or in combination with meglumine antimoniate for the treatment of experimental visceral leishmaniasis caused by Leishmania infantum.
    Gangneux JP; Sulahian A; Garin YJ; Derouin F
    J Antimicrob Chemother; 1997 Aug; 40(2):287-9. PubMed ID: 9301998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Miltefosine-Lopinavir Combination Therapy Against
    Rebello KM; Andrade-Neto VV; Gomes CRB; de Souza MVN; Branquinha MH; Santos ALS; Torres-Santos EC; d'Avila-Levy CM
    Front Cell Infect Microbiol; 2019; 9():229. PubMed ID: 31316919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo evaluation of anti-Leishmania activity of alkyltriazoles and alkylphosphocholines by oral route.
    Gontijo VS; Colombo FA; Ferreira Espuri P; Freitas PG; Nunes JB; Alves LB; Veloso MP; Alves RB; Freitas RP; Marques MJ
    Exp Parasitol; 2021; 226-227():108123. PubMed ID: 34144040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo antileishmanial activity and histopathological evaluation in Leishmania infantum infected hamsters after treatment with a furoxan derivative.
    de Almeida L; Passalacqua TG; Dutra LA; Fonseca JNVD; Nascimento RFQ; Imamura KB; de Andrade CR; Dos Santos JL; Graminha MAS
    Biomed Pharmacother; 2017 Nov; 95():536-547. PubMed ID: 28866421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections.
    Miguel DC; Zauli-Nascimento RC; Yokoyama-Yasunaka JK; Katz S; Barbiéri CL; Uliana SR
    J Antimicrob Chemother; 2009 Feb; 63(2):365-8. PubMed ID: 19095684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histamine H1-receptor antagonists against Leishmania (L.) infantum: an in vitro and in vivo evaluation using phosphatidylserine-liposomes.
    Pinto EG; da Costa-Silva TA; Tempone AG
    Acta Trop; 2014 Sep; 137():206-10. PubMed ID: 24905294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of liposomal buparvaquone in an experimental hamster model of Leishmania (L.) infantum chagasi.
    Reimão JQ; Colombo FA; Pereira-Chioccola VL; Tempone AG
    Exp Parasitol; 2012 Mar; 130(3):195-9. PubMed ID: 22281156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-leishmanial activity of the bisnaphthalimidopropyl derivatives.
    Tavares J; Ouaissi A; Silva AM; Lin PK; Roy N; Cordeiro-da-Silva A
    Parasitol Int; 2012 Jun; 61(2):360-3. PubMed ID: 22155672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of oleylphosphocholine (OlPC) in a laboratory model of visceral leishmaniasis.
    Fortin A; Hendrickx S; Yardley V; Cos P; Jansen H; Maes L
    J Antimicrob Chemother; 2012 Nov; 67(11):2707-12. PubMed ID: 22782488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Finding of leishmanicidal activity of 14-hydroxylunularin in mice experimentally infected with Leishmania infantum.
    Serna ME; Maldonado M; Torres S; Schinini A; Lima AP; Pandolfi E; de Arias AR
    Parasitol Int; 2015 Oct; 64(5):295-8. PubMed ID: 25843766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.